BioSpace News Archive

Genetown

TransMedics to Present at Upcoming March 2023 Investor Conferences

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced the company will be participating in two upcoming investor conferences.

February 21, 2023

·

1 min read

Business

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

February 21, 2023

·

14 min read

3H Medi Solution Selects THREAD to Expand Delivery of Decentralized Clinical Trials in Japan

3H Medi Solution Inc., a leading Japanese clinical trial company, today announced its selection of THREAD to expand decentralized research capabilities and improve access to clinical research for patients in Japan.

February 21, 2023

·

3 min read

Drug Development

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

Chemomab Therapeutics, Ltd. today announced U.S. Food and Drug Administration (FDA) clearance of the company’s Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis (SSc).

February 21, 2023

·

7 min read

Business

REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023 , at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2022, and recent operational highlights.

February 21, 2023

·

1 min read

Deals

Mirion Technologies Announces $150 Million Investment from T. Rowe Price, Priced At-the-Market

Mirion Technologies, Inc. today announced that it has agreed to sell $150 million of shares of Class A common stock to certain funds and accounts advised by T. Rowe Price Investment Management, Inc. (“T. Rowe Price”), a global investment management organization.

February 21, 2023

·

12 min read

Business

ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates.

February 21, 2023

·

4 min read

Deals

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Verrica Pharmaceuticals Inc. today announced the pricing of its underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock.

February 21, 2023

·

3 min read

FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia

Orasis Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).

February 21, 2023

·

3 min read

Business

Renowned Hemostat Innovator Joins Medcura to Drive Clinical Studies, Regulatory Pursuits

Medcura, Inc. welcomes Rachel Hoffman as its new Senior Vice President of Clinical and Regulatory Affairs.

February 21, 2023

·

3 min read